Inclusion Criteria:

          -  male or female greater than or equal to 18 years of age

          -  have one of the following disease states: Acute Myeloid Leukemia (AML) (age <60 years)
             with relapsed/refractory disease; •Chronic Lymphocytic Leukemia (CLL) with relapsed
             disease following a fludarabine-based regimen or relapsed disease following an
             alkylator-based regimen

          -  are recovered from the acute adverse effects of prior therapies (excluding alopecia
             and Grade ≤2 neuropathy).

          -  have blast counts that can be controlled by the use of hydroxycarbamide (500 to 3000
             mg daily).

          -  have adequate hepatic function and renal function

          -  have an estimated life expectancy of >3 months

          -  female subject must have a negative serum pregnancy result within 7 days before the
             start of the study; Both men and women must agree to use a medically acceptable form
             of contraception throughout the treatment period and for 3 months after
             discontinuation of treatment

        Exclusion Criteria:

          -  are eligible for any standard therapy known to be life prolonging or life saving

          -  have diagnosis of AML French-American-British (FAB) classification (FAB) M3 (acute
             promyelocytic leukemia (APL))

          -  are receiving concurrent chemotherapy, radiotherapy, immunotherapy, biological or
             hormonal treatment for cancer.

          -  have undergone anticancer therapy including chemotherapy (except for hydroxycarbamide
             at a maximum daily dose of 3000 mg), endocrine therapy, immunotherapy, or the use of
             other investigational agents within 4 weeks before study entry.

          -  prior radiation therapy with volume of bone marrow treated over 25%.

          -  use of immunosuppressive therapy, including systemic steroids within 7 days before the
             first dose of SG2000.

          -  hyperleukocytosis (blast counts >30 000/mm3).

          -  history of allogeneic stem cell or solid organ transplantation.

          -  positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C
             or have HIV-AIDS, or active hepatitis B or C.

          -  history of other invasive malignancy within 3 years except for cervical carcinoma in
             situ, nonmelanomatous carcinoma of the skin or ductal carcinoma in situ of the breast
             that has been surgically cured.

          -  have any coexisting medical condition that will substantially increase the risk
             associated with the subject's participation in the study.

          -  have psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of necessary studies.

          -  have persistent Grade 2 or greater toxicities from any cause (except alopecia or
             peripheral neuropathy).

          -  are pregnant or breast-feeding.